HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Antiplaque Claims Spectrum Outlined By WhiteHill

This article was originally published in The Rose Sheet

Executive Summary

Products carrying antiplaque-only claims should be permitted in the OTC antigingivitis/antiplaque monograph, WhiteHill Oral Technologies states in Nov. 24 comments to FDA

You may also be interested in...



Antiplaque Essential Oil In Vitro Plus In Vivo Test Requirement Urged By Pfizer

The antigingivitis/antiplaque monograph should require that products containing a fixed combination of the essential oils menthol, thymol, methyl salicylate and eucalyptol be tested with both in vitro and in vivo test methods, Pfizer Consumer Healthcare maintains

Antigingivitis/Antiplaque Combination With Other Actives Excluded In ANPR

FDA's advance notice of proposed rulemaking on OTC antigingivitis/antiplaque products excludes the combination of antigingivitis/antiplaque ingredients with other oral health care ingredients. The 1notice was published in the May 29 Federal Register

FDA Should Allow "Qualified" Plaque-Only Cosmetics Claims, WhiteHill Says

Plaque-only claims "qualified with cosmetic benefits" should be included in the eventual OTC monograph for antiplaque/antigingivitis drugs, WhiteHill Oral Technologies urges in recent comments to FDA. Examples of "qualified plaque claims" include "Reduces plaque for a cleaner mouth"; "Reduces plaque for cleaner teeth"; or "Reduces plaque associated with bad breath," WhiteHill says.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS011722

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel